Scott Morenstein

Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.

Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA.

Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.

Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.

Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.

Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.

Valence Life Sciences LLC (Valence Life Sciences) is an venture capital firm founded in 2012 by Rachel Anne Leheny and Eric Wayne Roberts. The firm is headquartered in New York.

Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.

Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.

Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.

Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.

Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.

Avenge Bio, Inc. is an oncology-focused biotechnology company based in the United States. The American company develops cell-based immunotherapeutic products for the treatment of solid tumors using its proprietary Lococyte™ platform. The platform delivers engineered cells to the local tumor environment, generating high concentrations of immune effector molecules in proximity to the tumor, which initiates a robust, local, and durable systemic immune response while avoiding toxicities associated with systemic immunotherapies. Avenge's most advanced product candidate, AVB-001, produces native IL-2 immunotherapy and is initially being studied in metastatic peritoneal cancers such as ovarian cancer. The company has additional pipeline candidates for the treatment of a wide range of cancers, including pancreatic, lung, and breast cancers. Avenge was founded in 2019 by Paul Kevin Wotton and Michael Thomas Heffernan, with Heffernan serving as CEO since incorporation.

Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.

Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA.

Antios Therapeutics, Inc. operates as a biopharmaceutical company devoted to developing therapies for viral diseases. The company was founded by Abel De La Rosa, Doug Mayers and Idean Marvasty on October 30, 2018 and is headquartered in Atlanta, GA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

Primmune Therapeutics, Inc. develops small molecules, orally administered toll-like receptor for cancer immunotherapy and tumors. The firm offers treatment and prevention of viral infections. The company was founded by Paulo Rangel, James Appleman, and Stephen Webber in October, 2017 and is headquartered in San Diego, CA.

Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.